Cogent Biosciences (COGT) Cash from Operations: 2017-2021
Historic Cash from Operations for Cogent Biosciences (COGT) over the last 5 years, with Dec 2021 value amounting to -$20.8 million.
- Cogent Biosciences' Cash from Operations fell 121.83% to -$20.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$58.8 million, marking a year-over-year decrease of 63.91%. This contributed to the annual value of -$207.8 million for FY2024, which is 35.26% down from last year.
- Latest data reveals that Cogent Biosciences reported Cash from Operations of -$20.8 million as of Q4 2021, which was down 47.26% from -$14.1 million recorded in Q3 2021.
- In the past 5 years, Cogent Biosciences' Cash from Operations registered a high of -$5.8 million during Q2 2017, and its lowest value of -$20.8 million during Q4 2021.
- For the 3-year period, Cogent Biosciences' Cash from Operations averaged around -$11.3 million, with its median value being -$10.8 million (2019).
- As far as peak fluctuations go, Cogent Biosciences' Cash from Operations spiked by 31.47% in 2020, and later plummeted by 121.83% in 2021.
- Quarterly analysis of 5 years shows Cogent Biosciences' Cash from Operations stood at -$6.5 million in 2017, then plummeted by 38.43% to -$9.0 million in 2018, then grew by 6.37% to -$8.4 million in 2019, then fell by 10.91% to -$9.4 million in 2020, then crashed by 121.83% to -$20.8 million in 2021.
- Its Cash from Operations stands at -$20.8 million for Q4 2021, versus -$14.1 million for Q3 2021 and -$12.5 million for Q2 2021.